16.2
Systèmes d’administration de médicaments à libération modifiée: vue d’ensemble
Les formes galéniques à libération modifiée sont conçues pour pallier les limites des médicaments à demi-vie biologique courte. Elles maintiennent des…
Les formes posologiques à libération modifiée aident à résoudre les problèmes liés aux médicaments à demi-vie courte en réduisant la fréquence des doses et en maintenant des niveaux thérapeutiques stables.
Des niveaux stables de médicaments réduisent les effets secondaires, diminuent le risque de résistance aux médicaments et améliorent les résultats du traitement.
Par exemple, les formulations à libération prolongée ou ER améliorent l’adhésion chez le patient en réduisant la fréquence des dosages, en maintenant les effets thérapeutiques et en améliorant la tolérabilité.
Malgré ces bienfaits, les formulations ER présentent plusieurs limites.
Le déversement de dose à partir de formulations défectueuses peut entraîner une libération excessive de médicaments, entraînant une toxicité.
Les médicaments à forte dose peuvent être soumis à des contraintes de taille sous forme de RE, ce qui les rend plus difficiles à avaler.
De plus, le métabolisme en premier passage peut varier affecter la biodisponibilité du médicament selon sa voie métabolique et la conception de sa formulation. Des envêtements entériques inadéquats peuvent provoquer une irritation ou une absorption incomplète du médicament.
Pourtant, les formulations ER restent essentielles pour améliorer l’efficacité médicamenteuse, la sécurité et l’adhésion au traitement.
View the full transcript and gain access to JoVE Core videos
Q1: Why do modified-release dosage forms reduce the need for frequent dosing?
Modified-release forms maintain stable therapeutic drug concentrations over extended periods, addressing limitations of drugs with short biological half-lives. By sustaining consistent drug levels, these formulations reduce peak-trough fluctuations, minimize adverse effects, lower drug resistance risk, and improve overall treatment effectiveness while decreasing the daily doses required.
Q2: How do extended-release formulations improve patient compliance?
Extended-release formulations reduce dosing frequency and ensure sustained therapeutic effects, which enhances patient compliance—especially in chronic therapy. By minimizing missed doses and maintaining tolerability, ER products lower long-term healthcare costs and improve treatment adherence in patients managing chronic conditions and improving outcomes.
Q3: What is dose-dumping and why is it a concern in extended-release formulations?
Dose-dumping occurs when a failure in the controlled-release mechanism causes sudden, excessive drug release, potentially leading to toxic plasma concentrations. This risk is severe with drugs having narrow therapeutic windows, as the sudden spike in drug levels can cause serious toxicity rather than the intended sustained therapeutic effect.
Q4: How do gastrointestinal factors affect extended-release drug performance?
Variations in pH, motility, and enzymatic activity in the gastrointestinal environment alter drug release and absorption from extended-release products. If enteric coatings are poorly designed or compromised, drugs may be released prematurely, causing gastrointestinal irritation or reduced bioavailability, affecting modified release drug delivery systems drug release characteristics.
Q5: What size limitations do extended-release formulations face?
For drugs requiring large doses, extended-release tablets or capsules may become too large for easy swallowing, impacting patient acceptance and compliance. This physical constraint is a significant limitation of ER formulations, particularly for patients with difficulty swallowing or those requiring high therapeutic doses.
Q6: How does first-pass metabolism affect extended-release drug bioavailability?
First-pass metabolism variably affects drug bioavailability depending on the drug's metabolic pathway and formulation design. Extended-release formulations must account for these metabolic factors to ensure predictable drug levels, as inadequate formulation design can result in inconsistent bioavailability and reduced therapeutic effectiveness.
Q7: What makes extended-release formulations essential despite their limitations?
When appropriately designed and administered, extended-release formulations optimize drug delivery by enhancing efficacy, safety, and adherence to prescribed regimens. They are indispensable in managing chronic conditions by maintaining stable therapeutic drug levels, reducing side effects, and improving long-term patient outcomes.